Last reviewed · How we verify

NCT05720416

Effects of a Multi-intervention Programme for the Elderly

Completed NA Last updated 12 March 2025
What this trial tests

NA trial testing protein supplementation in Sarcopenia in 207 participants. Completed in 31 December 2024.

Timeline
22 August 2023
Primary endpoint
30 August 2024
31 December 2024

Quick facts

Lead sponsorCentral Taiwan University of Science and Technology
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment207
Start date22 August 2023
Primary completion30 August 2024
Estimated completion31 December 2024
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Central Taiwan University of Science and Technology

Who can join

60 and older, any sex, with Sarcopenia or Sarcopenic Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1\. To develop a multiactivity training programme. 2. To explore the effect of this programme on sarcopenia, sarcopenic obesity, cognitive impairment and Parkinson's disease. 3. To compare the effects of the experimental and control treatments on the muscle strength, body composition, physical function performance and quality of life of the elderly.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of protein supplementation

Trials testing the same drug.

Other recruiting trials for Sarcopenia

Currently open trials in the same condition.

Other Central Taiwan University of Science and Technology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05720416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing